Content |
- Main article: FSIN
- Main article: Prisons in Russia
Chronicle
2022: Purchases of drugs for the FSIN doubled over the year and reached 2 billion rubles
State purchases of medicines for medical institutions of the Federal Penitentiary Service (FSIN) in 2022 amounted to about 2 billion rubles, which is about twice as much as a year earlier. Such data at the end of January 2023 led analysts Headway Company.
Experts explain the noticeable increase in purchases for the FSIN in 2022 by the low base of the previous period. They suggest that this may be due to the redistribution of part of the funds pledged for the FSIN for 2021 to public procurement in 2020. In 2021, drugs were purchased for 976.55 million rubles, which is 3.4 times less than a year earlier.
So, in 2020, the most funds for HIV were purchased for the FSIN: for 415 million rubles - dolutegravir, for 332.5 million rubles - lopinavir + ritonavir. Later, TB drugs came out on top - in 2022 they accounted for about 60% of the purchased drugs.
Analysts believe that, despite the positive dynamics of the growth of purchases for the FSIN in 2022, the quality of medical care for prisoners is unlikely to change. Over the past few years, funding for this system has practically not increased, writes in the Kommersant issue of January 27, 2023.
As noted in the Headway Company, in 2020, the main supplier of medicines for the FSIN was Natsimbio. In that year, according to SPARK-Interfax, the total amount of the company's contracts with the FSIN Penitentiary Service amounted to 3 billion rubles, or 89.2% of the total funding for 2020. In 2021-2022, the list of suppliers expanded.
Thus, the main counterparties were Edwansd Trading (almost 600 million rubles with a share of 21%) and Virend International (424.37 million rubles, or 15%), according to Headway Company. Both companies were created by immigrants from India and produce tuberculosis drugs in Russia.[1]